Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Flerie AB
Acquired Company
Biosergen AB
SwedenSwedenBiotechnologyFinancial ServicesHealth CareFinanceVenture CapitalAngel InvestmentMedicalBiotechnologyHealth CareDescription
Flerie AB has received permission from the Swedish Companies Registration Office to merge with Biosergen AB. Upon merger registration on 23 October 2026, Biosergen will be dissolved, and its assets will transfer to Flerie. Shareholders of Biosergen will receive merger consideration in the form of newly issued Flerie shares. The merger is expected to be completed by 28 October 2026.
Fundz sees it the moment Flerie AB makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Biosergen AB?
Biosergen AB was acquired by Flerie AB, based in Sweden. The deal was reported on October 16, 2026. Flerie AB focuses on developing innovative treatments targeting various medical conditions. The company is engaged in advancing healthcare solutions through strategic mergers. Flerie AB is privately held and operates in Biotechnology.
When did Flerie AB acquire Biosergen AB?
Flerie AB's acquisition of Biosergen AB was reported on October 16, 2026. Flerie AB has received permission from the Swedish Companies Registration Office to merge with Biosergen AB. Upon merger registration on 23 October 2026, Biosergen will be dissolved, and its assets will transfer to Flerie. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Biosergen AB do?
Biosergen AB is a biotechnology company that develops innovative drug candidates for treating serious infections, particularly invasive fungal infections. The company is engaged in exploring various strategic options to optimize its assets. It is privately held, operating in Biotechnology, and is based in Sweden.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.